2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1848

Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and Its Clinic Significance

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1981

Increased Extracellular Water Measured By Bioimpedance Analysis in Polymyalgia Rheumatica Patients – Sign of Volume Overload

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1588

Increased Fracture Risk in Patients with Early Rheumatoid Arthritis: A Prospective General Population-Matched Cohort Study

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1094

Increased IgA Plasmablasts Are Associated with Rheumatoid Arthritis-Related Autoantibodies in the Absence of Inflammatory Arthritis

B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

9:00AM-11:00AM: Abstract Number: 1850

Increased Levels of Immunoglobulin Binding Protein 1 Are Associated with Disease Activity Including Renal Damage in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1737

Increased Osteoclast Precursors with an Elevated DC-STAMP Expression May Identify Psoriasis Patients at Risk for Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1511

Increased Prevalence of Anti-Nuclear and Anti-SSA Autoantibodies in African American Rheumatoid Arthritis Patients Versus Matched Caucasian Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1504

Increased Risk of Thromboembolism Among Patients with VTE Association with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1924

Increased Stat1 and Stat 1 Phosphorylation in Patients with Systemic Sclerosis (SSc)

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 1419

Increasing Comorbidity Is Associated with Worsening Physical Function during Intermediate-Term Follow-up of Primary Total Knee Arthroplasty

Orthopedics, Low Back Pain and Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 1294

Infection and Screening Costs Related to Tumor Necrosis Factor-Alpha Inhibitor Use

Health Services Research Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 1224

Infection Rate in HIV Patients Who Received TNF-a Inhibitor Therapy for Concomitant Autoimmune Diseases

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1789

Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1302

Inflammation Signs on Magnetic Resonance Imaging in Chronic or Recurrent Gonarthritis Treated with Intra-Articular Infliximab or Corticosteroids

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1461

Inflammatory Bowel Disease in Children with Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].